| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 16,283.6 | 13,655.1 | 12,025.3 | 11,148.8 | 10,616.8 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 16,283.6 | 13,655.1 | 12,025.3 | 11,148.8 | 10,616.8 |
Other Operating Income | 430 | 358.5 | 544.4 | 316.4 | 189.7 |
Other Income | 188.9 | 147.5 | 148.8 | 2,664.2 | 153.5 |
Total Income | 16,902.5 | 14,161.1 | 12,718.5 | 14,129.4 | 10,960 |
Total Expenditure | 11,780.6 | 10,274 | 9,970.7 | 9,014.6 | 8,567.7 |
PBIDT | 5,121.9 | 3,887.1 | 2,747.8 | 5,114.8 | 2,392.3 |
Interest | 89.3 | 46.6 | 102.2 | 88.5 | 140 |
PBDT | 5,032.6 | 3,840.5 | 2,645.6 | 5,026.3 | 2,252.3 |
Depreciation | 677.9 | 558.8 | 544.1 | 550.7 | 523.6 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,058.7 | 1,027.7 | 460.6 | 323.8 | 338.1 |
Deferred Tax | -70 | -371.4 | -10 | 28.4 | -15.4 |
Reported Profit After Tax | 3,366 | 2,625.4 | 1,650.9 | 4,123.4 | 1,406 |
Minority Interest After NP | 74.3 | 49.5 | 70 | 75.1 | -5 |
Net Profit after Minority Interest | 3,354.6 | 2,677.2 | 1,663.7 | 4,089.9 | 1,454.6 |
Extra-ordinary Items | 0 | 1.13 | -4.67 | 2,405.58 | -104.99 |
Adjusted Profit After Extra-ordinary item | 3,354.6 | 2,676.07 | 1,668.37 | 1,684.32 | 1,559.59 |
EPS (Unit Curr.) | 33.34 | 26.45 | 16.33 | 39.95 | 14.21 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 100.6 | 101.2 | 101.2 | 102.4 | 102.4 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.45 | 28.46 | 22.85 | 45.87 | 22.53 |
PBDTM(%) | 30.9 | 28.12 | 22 | 45.08 | 21.21 |
PATM(%) | 20.67 | 19.22 | 13.72 | 36.98 | 13.24 |
As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.
Here are some of the stocks that may see significant price movement today: Bajaj Auto, NTPC, GR Infraprojects, etc.
Here are some of the stocks that may see significant price movement today: Dalmia Bharat, Galaxy Surfactants, Tata Motors, etc.
The inspection concluded with “NIL observations,” the firm said in a regulatory filing, underlining its strong compliance with quality and manufacturing practices.
The deal is subject to signing a put option agreement, share purchase agreements and other relevant contracts for acquisition of controlling shareholding of Amplitude Surgical SA, directly or through Zydus' affiliates.
This investment is in line with Zynext Ventures' mission to invest in transformative healthcare innovations that meet large unmet medical needs.
The approval is valid for all Zydus Lifesciences affiliates and subsidiaries, said the company in the stock exchange filing dated March 10, 2025.
The approved strengths are 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg.
Here are some of the stocks that may see significant price movement today: TCS, Wipro, Zydus Lifesciences, RPP Infra Projects, etc.
Expected to launch in March 2025, the collaborative effort is funded by the Bill & Melinda Gates Foundation, demonstrating a continued global commitment to innovation in public health.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
